Using advanced MRI to improve radiotherapy for glioblastoma
Hitting the Mark: Introducing State-of-the-art MRI for Precision Radiotherapy of Glioblastoma
This study is testing whether using advanced MRI techniques can help doctors better target glioblastoma tumors during radiotherapy, aiming to protect healthy tissue while effectively treating the cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 53 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Erasmus Medical Center Academic / other |
| Drugs / interventions | Radiation |
| Locations | 1 site (Rotterdam, South Holland) |
| Trial ID | NCT06183983 on ClinicalTrials.gov |
What this trial studies
This prospective cohort study aims to evaluate the effectiveness of advanced MRI techniques in enhancing the precision of radiotherapy target delineation for patients with glioblastoma. Participants will undergo an extended MRI protocol that includes both standard and advanced imaging sequences prior to their radiotherapy treatment. The study will compare the coverage of tumor recurrence volumes and the distribution of radiation doses to healthy organs between traditional and advanced MRI-based radiotherapy plans. By integrating advanced MRI into the treatment planning process, the study seeks to minimize damage to healthy tissue while effectively targeting tumor infiltration.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with IDH-wildtype glioblastoma who are scheduled for standard radiotherapy.
Not a fit: Patients with contraindications for MRI or those referred for treatment of recurrent glioblastoma may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more precise radiotherapy for glioblastoma patients, potentially reducing side effects and improving quality of life.
How similar studies have performed: While the integration of advanced MRI techniques in radiotherapy is a promising approach, it is still relatively novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Written informed consent; * Adult (18 years or older); * Diagnosed with IDH-wildtype glioblastoma, as confirmed by pathology including molecular analysis post resection/biopsy; * Referred to the outpatient clinic of the Dept. of Radiotherapy to undergo standard treatment with radiotherapy (30x2 Gy or 15x2.67Gy or 10x3.4Gy). Exclusion Criteria: * Contraindication for (3 Tesla) MRI; * Contraindication for use of gadolinium-based contrast agent (e.g. subject having renal deficiency or known allergy); * Referred for treatment of recurrent glioblastoma; * Previous radiotherapy to the brain; * Unable to give informed consent
Where this trial is running
Rotterdam, South Holland
- Erasmus Medical Center — Rotterdam, South Holland, Netherlands (Recruiting)
Study contacts
- Principal investigator: Alejandra Méndez Romero, MD, PhD — Erasmus Medical Center
- Study coordinator: Patrick Tang, MSc
- Email: p.l.y.tang@erasmusmc.nl
- Phone: +31634271995
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.